Sab Biotherapeutics To List On Nasdaq Through Merger With Big Cypress Acquisition Corp
T-Reuters
Jun 22, 2021
Big Cypress Acquisition Corp :Sab Biotherapeutics To List On Nasdaq Through Merger With Big Cypress Acquisition Corp., Advancing Unique Human Antibody Platform With Demonstrated Utility In Immunotherapy And Rapid Response To Emerging Diseases.Sab Biotherapeutics - Upon Merger Closing, Combined Company Is Expected To Be Listed On Nasdaq.Sab Biotherapeutics - Upon Closing Of Proposed Deal, Combined Co Will Operate As Sab Biotherapeutics,Will Continue To Operate Under Sab Management Team.Sab Biotherapeutics - Upon Closing Of Proposed Deal, Big Cypress Acquisition Corp.'S Samuel J. Reich & Jeffrey G. Spragens To Join Co'S Board.Sab Biotherapeutics - Sab Co-Founder, Current Executive Chairman, Edward Hamilton, Plans To Transition To Board Observer Role While Remaining Active In Co.Sab Biotherapeutics - Proposed Transaction Implies An Enterprise Value For Sab, On A Post-Merger Basis, Of About $325 Million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.